NRSN NeuroSense Therapeutics Ltd.
USHealthcareAs of 2026-07-10 16:00
Why NRSN matters now
NeuroSense Therapeutics Ltd. (NRSN) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.73 with +1.19% on the session and $18.0M in market capitalization; recent performance reads 1-month +5.59% and YTD +4.63%.
The latest financial table shown here is FY 2025, with revenue of $0.00, net income of $-11.1M, and EPS of $-0.44. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.0%.
The latest indexable market news headline is "NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Eisenberg Or filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-13.10
P/S
0.00
EV/EBITDA
-3.08
DCF Value
$-0.03
FCF Yield
-0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
173600.0%
ROA
-633.3%
ROIC
465.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $0.00 | $-11.1M | $-0.44 |
| Q2 2025 | $0.00 | $-2.4M | $-0.09 |
| Q1 2025 | $0.00 | $-2.4M | $-0.09 |
| Q4 2024 | $0.00 | $-1.8M | $-0.08 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
1.54
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.